Prevalence of dyslipidemia in adults with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 9, Issue 1, 2010, Pages 24-28

  Rhodes, Bronwen ^b   Nash, Edward F ^e   Tullis, Elizabeth ^a,b   Pencharz, Paul B ^c,d   Brotherwood, Michelle ^b   Dupuis, Annie ^c   Stephenson, Anne ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Diabetes; Lipids

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CANADA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS INSUFFICIENCY; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DIABETES MELLITUS; DYSLIPIDEMIAS; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; LIPIDS; MALE; PANCREAS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 73449133698     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.09.002     Document Type: Article

References (28)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Report (2007)
2. Kalivianakis M., Minich D.M., Bijleveld C.M., van Aalderen W.M., Stellaard F., Laseur M., et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 69 1 (Jan 1999) 127-134
3. Figueroa V., Milla C., Parks E.J., Schwarzenberg S.J., and Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr 75 6 (Jun 2002) 1005-1011
4. Levy E., Gurbindo C., Lacaille F., Paradis K., Thibault L., and Seidman E. Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis. Pediatr Res 34 2 (Aug 1993) 162-166
5. Gotto A.M.J. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease. J Am Coll Cardiol 46 (2005) 1219-1224
6. Onady G.M., and Farinet C.L. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm Med 6 (2006) 9
7. Corey M., McLaughlin F.J., Williams M., and Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41 6 (1988) 583-591
8. Moran A., Doherty L., Wang X., and Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 133 1 (Jul 1998) 10-17
9. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 19 4 (Apr 1996) 387-389
10. Hardin D., LeBlanc A., and Seilheimer D.K. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 281 (1999) E1022-E1028
11. Schwarzenberg S.J., Thomas W., Olsen T.W., Grover T., Walk D., Milla C., et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 30 5 (May 2007) 1056-1061
12. Rhodes B., Brotherwood M., Nash E., Pencharz P.B., Dupuis A., Tullis E., et al. Lipid profiles in an adult cystic fibrosis population. Pediatr Pulmonol Suppl 31 439 (2008)
13. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. J Pediatrics 153 2 (2008) S4-S14
14. Hankinson J.L., Odencrantz J.R., and Fedan K.B. Spirometric reference values form a sample of the general U.S. population. Am J Respir Crit Care Med 159 1 (1999) 179-187
15. Moran A., Hardin D., Rodman D., Allen H.F., Beall R.J., Borowitz D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 45 1 (Aug 1999) 61-73
16. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (Jun 1972) 499-502
17. Third Report of the National Cholesterol Education Program (NCEP. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 25 (Dec 17 2002) 3143-3421
18. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 9 (Oct 28 2003) 921-924
19. Medina R.A., Aranda E., Verdugo C., Kato S., and Owen G.I. The action of ovarian hormones in cardiovascular disease. Biol Res 36 3-4 (2003) 325-341
20. Espeland M.A., Marcovina S.M., Miller V., Wood P.D., Wasilauskas C., Sherwin R., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal estrogen/progestin interventions. Circulation 97 10 (Mar 17 1998) 979-986
21. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340 23 (Jun 10 1999) 1801-1811
22. Watts G.F., Barrett P.H., and Chan D.C. HDL metabolism in context: looking on the bright side. Curr Opin Lipidol 19 4 (Aug 2008) 395-404
23. Ajees A.A., Anantharamaiah G.M., Mishra V.K., Hussain M.M., and Murthy H.M. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103 7 (Feb 14 2006) 2126-2131
24. Grunfeld C., Gulli R., Moser A.H., Gavin L.A., and Feingold K.R. Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J Lipid Res 30 4 (Apr 1989) 579-585
25. White N.M., Jiang D., Burgess J.D., Bederman I.R., Previs S.F., and Kelley T.J. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 292 2 (Feb 2007) L476-L486
26. Christophe A.B., Warwick W.J., and Holman R.T. Serum fatty acid profiles in cystic fibrosis patients and their parents. Lipids 29 8 (Aug 1994) 569-575
27. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 5 (May 1977) 707-714
28. Dodge J.A., Lewis P.A., Stanton M., and Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 29 3 (Mar 2007) 522-526